Investigating the efficacy and safety of twice daily Nanojade in transfusion-dependent thalassemia patients

Phase 2

Recruiting

• Conditions: Major beta-thalassemia.; Beta thalassemia; D56.1

• Registration Number: IRCT20100110003032N3
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 March 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

Age 2 years and older
Blood transfusion-dependent major beta-thalassemia
Under treatment with single iron chelator for at least 6 months and ferritin above 2500 ng/dL or patient with gastrointestinal side effects and ferritin above 2500 nd/d

Exclusion Criteria

Unwillingness to participate in the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
iver Iron Concentration (LIC) mg Fe/g. Timepoint: Before starting the intervention and 6-12 months after the intervention. Method of measurement: Liver biopsy.